Charles Ferté
Institut Gustave Roussy
95 Papers
245 Citations
Charles Ferté is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 26, co-authored 92 publications. Previous affiliations of Charles Ferté include University of Paris-Sud & Fred Hutchinson Cancer Research Center.
Chat about Author
Papers
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat,Stéphane Champiat,Laurent Dercle,Samy Ammari,Christophe Massard,Antoine Hollebecque,Sophie Postel-Vinay,Sophie Postel-Vinay,Nathalie Chaput,Alexander M.M. Eggermont,Aurélien Marabelle,Aurélien Marabelle,Jean-Charles Soria,Jean-Charles Soria,Charles Ferté,Charles Ferté +15 more
TL;DR: A novel aggressive pattern of hyperprogressive disease or HPD exists in a fraction of patients treated with anti-PD-1/PD-L1 monotherapy, and this observation raises some concerns about treating elderly patients (>65 years old), and suggests further study of this phenomenon.
1.1K
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun,Roger Sun,Elaine Johanna Limkin,Elaine Johanna Limkin,Maria Vakalopoulou,Maria Vakalopoulou,Laurent Dercle,Laurent Dercle,Stéphane Champiat,Shan Rong Han,Loic Verlingue,David Brandao,Andrea Lancia,Andrea Lancia,Andrea Lancia,Samy Ammari,Antoine Hollebecque,Jean-Yves Scoazec,Jean-Yves Scoazec,Aurélien Marabelle,Christophe Massard,Jean-Charles Soria,Jean-Charles Soria,Charlotte Robert,Nikos Paragios,Nikos Paragios,Eric Deutsch,Charles Ferté,Charles Ferté +28 more
TL;DR: A radiomic signature predictive of immunotherapy response by combining contrast-enhanced CT images and RNA-seq genomic data from tumour biopsies to assess CD8 cell tumour infiltration was developed and validated.
1K
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial
Christophe Massard,Stefan Michiels,Charles Ferté,Marie-Cécile Le Deley,Ludovic Lacroix,Antoine Hollebecque,Loic Verlingue,Ecaterina Ileana,Silvia Rosellini,Samy Ammari,Maud Ngo-Camus,Rastislav Bahleda,Anas Gazzah,Andrea Varga,Sophie Postel-Vinay,Yohann Loriot,Caroline Even,Ingrid Breuskin,Nathalie Auger,Bastien Job,Thierry de Baere,Frederic Deschamps,Philippe Vielh,Jean-Yves Scoazec,Vladimir Lazar,Catherine Richon,Vincent Ribrag,Eric Deutsch,Eric Angevin,Gilles Vassal,Alexander M.M. Eggermont,Fabrice Andre,Jean-Charles Soria +32 more
TL;DR: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers, although these results are encouraging, only 7% of the successfully screened patients benefited from this approach.
684
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.
Elaine Johanna Limkin,Roger Sun,Roger Sun,Laurent Dercle,Evangelia I. Zacharaki,Charlotte Robert,Charlotte Robert,Sylvain Reuzé,Sylvain Reuzé,Antoine Schernberg,Antoine Schernberg,Nikos Paragios,Eric Deutsch,Charles Ferté +13 more
TL;DR: This Review addresses the critical issues to ensure the proper development of radiomics as a biomarker and facilitate its implementation in clinical practice.
672
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.